Are there any scenarios you would use CDK 4/6i to treat HR-positive HER2-positive breast cancer in combination with anti-HER2 agents?

There is a strong preclinical data demonstrating that CDK4/6 inhibition reduces the growth of HER2-positive breast cancer cell lines. However, we are still awaiting the results of phase 3 trials testing the addition of CDK4/6 inhibitors to systemic therapy for hormone receptor (HR) positive, HER2 po...